Drug Profile

VT 30

Alternative Names: BBP-681; VT-30

Latest Information Update: 18 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Memorial Sloan-Kettering Cancer Center
Developer Venthera
Class Small molecules; Vascular disorder therapies
Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I/II Vascular disorders

Most Recent Events

04 Aug 2022 Venthera terminates a Phase Ib/II trial in Vascular disorders in USA (Topical) (NCT04409145)
14 Jun 2022 VT 30 is available for licensing as of 14 Jun 2022. https://venthera.com/#science
10 Jun 2022 Pharmacodynamics and adverse events data of a phase I/II trial in Vascular disorders released by BridgeBio Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com